RZLT vs. CLRB, ABEO, IMUX, ADAG, FGEN, CRVS, CTXR, PMVP, RLMD, and ACET
Should you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Cellectar Biosciences (CLRB), Abeona Therapeutics (ABEO), Immunic (IMUX), Adagene (ADAG), FibroGen (FGEN), Corvus Pharmaceuticals (CRVS), Citius Pharmaceuticals (CTXR), PMV Pharmaceuticals (PMVP), Relmada Therapeutics (RLMD), and Adicet Bio (ACET). These companies are all part of the "pharmaceutical preparations" industry.
Rezolute (NASDAQ:RZLT) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.
Rezolute currently has a consensus target price of $8.80, indicating a potential upside of 233.33%. Cellectar Biosciences has a consensus target price of $20.00, indicating a potential upside of 506.06%. Given Cellectar Biosciences' higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Rezolute.
Rezolute's return on equity of -60.90% beat Cellectar Biosciences' return on equity.
Rezolute is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Rezolute has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.
Cellectar Biosciences received 185 more outperform votes than Rezolute when rated by MarketBeat users. However, 75.34% of users gave Rezolute an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
83.0% of Rezolute shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 20.8% of Rezolute shares are owned by insiders. Comparatively, 4.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Cellectar Biosciences had 8 more articles in the media than Rezolute. MarketBeat recorded 18 mentions for Cellectar Biosciences and 10 mentions for Rezolute. Cellectar Biosciences' average media sentiment score of 0.63 beat Rezolute's score of 0.17 indicating that Cellectar Biosciences is being referred to more favorably in the news media.
Summary
Rezolute beats Cellectar Biosciences on 8 of the 14 factors compared between the two stocks.
Get Rezolute News Delivered to You Automatically
Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rezolute Competitors List
Related Companies and Tools
